

From Discovery to Impact: Introducing the Avicenna Journal of Clinical and Translational Medicine

Guido Fumagalli

University of Verona, Verona, Italy

Editor-in-Chief, Avicenna Journal of Clinical and Translational Medicine

Correspondence: Guido Fumagalli, University of Verona, Verona, Italy. Email: guido.fumagalli@univr.it

 0000-0003-2195-4973

Received: 25 October 2026 | Accepted: 28 October 2026 | Publication: 30 October 2026

Bridging Discovery, Evidence, and Clinical Practice

Scientific progress can be gauged on the basis of its discovery. Value of such scientific progress is evaluated on the basis of the extent to which these discoveries enhance our knowledge, make better clinical decisions and ultimately help human health. While there has been substantial progress in molecular medicine, pharmacology, diagnostics and therapeutics, bridging the gap between science and practice is still difficult [1]. This need for bridging requires robust evidence, interdisciplinary and considerations of barriers in the application of scientific knowledge in clinical practice.

In this context of scientific progress, we are pleased to introduce the Avicenna Journal of Clinical and Translational Medicine (AJCTM). AJCTM is an international, peer-reviewed, open access scientific journal focusing on clinically-oriented and translational research. There is a simple philosophy behind AJCTM: scientific knowledge is not enough, it has to be critically reviewed and developed into evidence.

Translational medicine is not just moving from basic discoveries to end up in clinical application. This discipline requires development and evaluation of diagnostic and treatment strategies, generation of robust evidence and its translation to patients from different backgrounds within various healthcare settings. Even interventions validated in strong clinical trials may experience problems of implementation due to heterogeneity in patients' background, resources available, clinical practice and other factors [2].

The scope of this journal includes topics related to clinical and translational medicine, disease mechanisms at the molecular and cellular levels, pharmacology and therapy, biomarkers, diagnostics, precision medicine, clinical trials, epidemiology, evidence-based medicine, and implementation science. In particular, there will be priority to research solving important clinical questions, revealing the relationship between biology and patient outcomes, or providing information about healthcare improvement.

Our goal goes beyond promoting knowledge through publication; we aim at promoting research questions and evaluation systems directed toward the understanding of disease mechanisms, the improvement of diagnostics or therapy decision-making, the implementation of science-based clinical practices and identification of obstacles to efficient healthcare implementation. Therefore, the most important issue and goal of this new journal will be the promotion of scientific research that generates reliable evidences influencing human health.

Scientific relevance is not dictated by the clinical applicability of the results. Fundamentally important studies generating new methods, and even confirming or contradicting known facts represent an irreplaceable contribution to the scientific progress. Thus, AJCTM is open to any scientifically sound investigation on biomedical or clinical topic, including carefully designed negative, neutral or confirmatory works.

Modern development of scientific publishing opens unique possibilities for exchanging the knowledge but it creates serious concerns about scientific validity of researches. Poor methodology, poor statistics and insufficient reporting decrease confidence in the results

[3]. In addition, avoidable methodological, statistical and reporting flaws significantly reduce the value of scientific investments [4].

For AJCTM, scientific integrity and rigor have priority over publication output and even over novelty. The significance of the research question posed, the appropriateness of the study design, methods, statistical analyses, reporting and conclusions reached will be taken into account by the editorial assessment process.

Creation of a Credible and Inclusive Scientific Platform

Current clinical issues require the work of biomedical scientists, clinicians, pharmacologists, epidemiologists, biostatisticians, and health system researchers. The objective of AJCTM is to encourage such interaction and acknowledge the various viewpoints provided by experiments, randomized trials, observations, and real-world studies.

Just as important is the geographical diversity of research since the research agenda and the health care needs will be different between populations and health care systems. Studies conducted in low and middle income countries can yield valuable information about patterns of disease, limits in diagnosis, availability of therapy and barriers for the implementation of the interventions.

Scientific credibility of publications goes beyond the results of the study itself. Responsibility for the research, ethical oversight, transparency of reporting, conflict of interest disclosure and management, and peer review constitute the fundamentals of the credibility of the publication process. Guidelines on international recommendations and specific study reporting constitute an important framework for the authors, the reviewers, and the editors [5]. Study-specific reporting guidelines, such as the CONSORT 2025 statement for randomized controlled trials, further promote transparent and complete reporting of clinical research [6]. AJCTM maintains its commitment to editorial independence, productive peer review, responsibility and balanced assessment of the evidence underlying each conclusion.

While open access publishing enhances the dissemination of science, it does not contribute to the credibility. The publication decisions should be based on the scientific merit and ethical considerations. Artificial intelligence is more frequently used in biomedical research and publication process, which brings new opportunities as well as new responsibilities. Such use of technology should be appropriately disclosed, accuracy and confidentiality should be considered, and human responsibility for the

research and editorial decision making should be preserved.

A Commitment Beyond Publication

The launch of AJCTM marks the beginning of a scientific responsibility rather than the attainment of an institutional milestone. A journal achieves its stature gradually by virtue of the integrity of its editorial decisions, reliability of its findings and confidence of the communities it serves.

Our ambition is not only to start a new periodical publication, but to create an eminent international forum, where robust and rigorous inquiry, clinical relevance and reliable scholarship are harmoniously united. We encourage researchers, clinicians, educators, and academicians from various fields and nations to submit their works that challenges existing assumptions and solve the pertinent clinical questions, and strengthen the evidence available to patients, physicians and healthcare systems.

As AJCTM begins its journey, our guiding commitment is clear: to advance trustworthy scientific knowledge, connect discovery with clinical practice, and contribute meaningfully to better healthcare.

Declarations

Competing interests. Guido Fumagalli is Editor-in-Chief of the Avicenna Journal of Clinical and Translational Medicine. He declares no other competing interests.

Editorial handling. The author did not participate in the editorial handling of this editorial.

Funding. No funding was received for this editorial.

Author contribution. Guido Fumagalli developed and wrote this editorial. Author has approved this manuscript.

AI assistance. ChatGPT (OpenAI) assisted with language editing and document formatting.

© 2026 Guido Fumagalli. The author retains copyright. This editorial is distributed under the Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, including for commercial purposes, provided appropriate credit is given to the author and source, a link to the licence is provided, and any changes are indicated.
<https://creativecommons.org/licenses/by/4.0/>

How to cite: Fumagalli G. From Discovery to Impact: Introducing the Avicenna Journal of Clinical and Translational Medicine. Avicenna Journal of Clinical and Translational Medicine. 2026;1(1):e0001.

References

1. Woolf SH. The meaning of translational research and why it matters. *JAMA*. 2008;299(2):211–213. doi:10.1001/jama.2007.26.
2. Glasgow RE. Translating research to practice: lessons learned, areas for improvement, and future directions. *Diabetes Care*. 2003;26(8):2451–2456. doi:10.2337/diacare.26.8.2451.

3. Ioannidis JPA. Why most published research findings are false. *PLoS Med.* 2005;2(8):e124. doi:10.1371/journal.pmed.0020124.
4. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. *Lancet.* 2009;374(9683):86–89. doi:10.1016/S0140-6736(09)60329-9.
5. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated January 2026. Available from: <https://www.icmje.org/recommendations/>.
6. Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. *BMJ.* 2025;389:e081123. doi:10.1136/bmj-2024-081123.